Changyu Wang
Senior VP & Executive DirectorDr. Changyu WANG has been Executive Director at Keymed Biosciences Inc. since March 3, 2021 and served as Director since March 03, 2021 until April 03, 2021. Dr. Wang is the senior vice president of Keymed Biosciences Inc. and Chengdu Keymed. From April 1998 to March 2001, he was a research scientist at Chiron Corporation. From April 2001 to August 2009, he was a senior scientist at Medarex, Inc., which was formerly listed on NASDAQ until acquisition by Bristol Myers Squibb, a company listed on the New York Stock Exchange (stock code: BMY). From September 2009 to December 2013, he was a senior scientist at Bristol-Myers Squibb. From January 2014 to February 2016, he was a director in cancer immunology at Pfizer Inc., a company listed on the New York Stock Exchange (stock code: PFE). Dr. Wang obtained his bachelor’s degree in microbiology from Wuhan University in the PRC in July 1983. He obtained his master’s degree in virology from the National Vaccine and Serum Institute in September 1988. He obtained his PhD. in microbiology and immunology from the University of Colorado Medical Center in the United States in August 1994.
Positions
- Company NameKeymed Biosciences Inc.Stock Code02162PositionSenior VP & Executive Director
